BDR Pharmaceuticals
-
2024 Budget Reactions
Union Finance Minister Nirmala Sitaraman in her interim budget 2024-25, has emphasised the need for vaccinating girls in the age…
Read More » -
BDR Pharmaceuticals launches BDENZA oral solution for prostate cancer treatment
The oral solution is gentle on the stomach, avoiding issues like nausea BDR Pharmaceuticals has introduced BDENZA, the world’s first…
Read More » -
A Prescription for Success
How the Pharmaceutic l Industry Champions Generic Drug Safety In the ever-evolving landscape of healthcare, change often brings resistance, and…
Read More » -
BDR Pharma launches Dalbonova Injection
The injection will be used for acute bacterial skin infections BDR Pharmaceuticals International has announced the launch of Dalbonova Injection.…
Read More » -
BDR Pharma launches Nilotinib to treat Leukaemia
Sets a new standard in the treatment of Philadelphia Chromosome-positive Leukaemia BDR Pharmaceuticals has launched Nilotinib, a rare subtype of…
Read More » -
BDR Pharma launches generic antibiotic /anti-bacterial range medicine Ceftazidime Avibactum
XAVITAZ is a combination of 2g Ceftazidime & 500mg Avibactam BDR Pharmaceuticals has launched a new generic in the antibiotic…
Read More » -
BDR Pharma partners with Varenyam Healthcare
To revolutionise anaesthesia practices in India BDR Pharmaceuticals and Varenyam Healthcare announced the launch of Sugmadex – an innovation, bringing…
Read More » -
Multiples Private Equity led consortium invests Rs 6,850 M in BDR Pharma
The company will selectively pursue inorganic opportunities to build scale Multiples Private Equity has announced an investment of Rs 6,850…
Read More » -
BDR Pharma launches advanced gastric drug FURMECIL
Furmecil is soon going to be available in the Indian market is in the form of capsules of two strengths…
Read More » -
BDR Pharma launches prostate cancer drug Enzalutamide 160 mg
The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects BDR Pharmaceuticals has…
Read More »